Hangzhou Lvzhe Pharmaceutical Technology

Hangzhou Lvzhe Pharmaceutical Technology is a China-based biotechnology company specializing in the discovery and development of innovative small molecule therapeutics. The company leverages advanced protein degradation technologies, including Proteolysis Targeting Chimeras (PROTACs) and molecular glues, to target previously undruggable proteins. Their primary therapeutic focus lies in oncology and autoimmune diseases, aiming to provide next-generation treatments for patients with high unmet medical needs. Lvzhe Pharmaceutical operates a robust R&D platform in Hangzhou, integrating medicinal chemistry, structural biology, and pharmacology. The company is currently advancing several programs through the pre-clinical stage toward IND-enabling studies.